http://orcid.org/0000-0001-8166-7314
Citations (69)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Li-Fang Shen, Shui-Hong Zhou & Yu Guo. (2020) Role of GLUT-1 in the Upregulation of PD-L1 Expression After Radiotherapy and Association of PD-L1 with Favourable Overall Survival in Hypopharyngeal Cancer. OncoTargets and Therapy 13, pages 11221-11235.
Read now
Read now
Weiqing Wang, Zhenhua Gao, Lu Wang, Jianing Li, Jinming Yu, Shumei Han & Xue Meng. (2020) Application and Prospects of Molecular Imaging in Immunotherapy. Cancer Management and Research 12, pages 9389-9403.
Read now
Read now
Marie-Laurence Tremblay, Zoe O’Brien-Moran, James A. Rioux, Andrea Nuschke, Christa Davis, W. Martin Kast, Genevieve Weir, Marianne Stanford & Kimberly D. Brewer. (2020) Quantitative MRI cell tracking of immune cell recruitment to tumors and draining lymph nodes in response to anti-PD-1 and a DPX-based immunotherapy. OncoImmunology 9:1.
Read now
Read now
Xiuyun Lin, Tao Zeng, Jiani Xiong, Qiong Zhang, Pan Jiang, Xiufeng Li, Shuchun Lin, Qianqian Xu, Huanjiao Weng, Haichun Lai, Huichun Gong, Jinxiang Lin, Niangmei Cheng, Xinling Tian, Yunlu Xu, Shubin Fang, Rong Jin, Zhiwei Chen, Jianbo Yang, Luke Morton, Bevan Yueh & Jizhen Lin. (2019) Combined α-programmed death-1 monoclonal antibody blockade and fractionated radiation therapy reduces tumor growth in mouse EL4 lymphoma. Cancer Biology & Therapy 20:5, pages 666-679.
Read now
Read now
Abhishek D. Garg, Sanket More, Nicole Rufo, Odeta Mece, Maria Livia Sassano, Patrizia Agostinis, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2017) Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. OncoImmunology 6:12.
Read now
Read now
Articles from other publishers (64)
Shih-Chuan Tsai, Shiou-Shiow Farn, Wei-Lin Lo, Fang-Yu Ou Yang, Yong-Ching Kang, Liang-Cheng Chen, Kuo-Ting Chen, Jiunn-Wang Liao, Jui-Yin Kung, Jenn-Tzong Chen & Feng-Yun J. Huang. (2023) Evaluation of Chelator-to-Antibody Ratio on Development of 89Zr-iPET Tracer for Imaging of PD-L1 Expression on Tumor. International Journal of Molecular Sciences 24:24, pages 17132.
Crossref
Crossref
Fabian Krutzek, Cornelius K. Donat, Martin Ullrich & Sven Stadlbauer. (2023) Design, Synthesis, and Biological Evaluation of Small-Molecule-Based Radioligands with Improved Pharmacokinetic Properties for Imaging of Programmed Death Ligand 1. Journal of Medicinal Chemistry.
Crossref
Crossref
Xiaojing Yang, Hanru Ren, Zhen Li, Xue Peng & Jie Fu. (2023) Combinations of radiotherapy with immunotherapy in nasopharyngeal carcinoma. International Immunopharmacology 125, pages 111094.
Crossref
Crossref
Li-Fang Shen, Zi-Ming Fu & Shui-Hong Zhou. (2023) The role of radiotherapy in tumor immunity and the potential of PET/CT in detecting the expression of PD-1/PD-L1. Japanese Journal of Radiology.
Crossref
Crossref
Muhammad Kazim & Euna Yoo. (2023) Recent Advances in the Development of Non‐Invasive Imaging Probes for Cancer Immunotherapy. Angewandte Chemie International Edition.
Crossref
Crossref
Muhammad Kazim & Euna Yoo. (2023) Recent Advances in the Development of Non‐Invasive Imaging Probes for Cancer Immunotherapy. Angewandte Chemie.
Crossref
Crossref
Yunhao Chen, Yujiao Guo, Zhiguo Liu, Xiaokun Hu & Man Hu. (2023) An overview of current advances of PD-L1 targeting immuno-imaging in cancers. Journal of Cancer Research and Therapeutics 19:4, pages 866-875.
Crossref
Crossref
Annette Affolter, Kai Liebel, Luisa Tengler, Elena Seiz, Moritz Tiedtke, Alexya Azhakesan, Julia Schütz, Marie-Nicole Theodoraki, Johann Kern, Arne Ruder, Jens Fleckenstein, Cleo-Aron Weis, Karen Bieback, Benedikt Kramer, Anne Lammert, Claudia Scherl, Nicole Rotter & Sonja Ludwig. (2023) Modulation of PD‑L1 expression by standard therapy in head and neck cancer cell lines and exosomes. International Journal of Oncology 63:3.
Crossref
Crossref
Dorine de Jong, Elise Desperito, Karine Al Feghali, Laurent Dercle, Romain-David Seban, Jeeban Das, Hong Ma, Abin Sajan, Brian Braumuller, Conor Prendergast, Connie Liou, Aileen Deng, Tina Roa, Randy Yeh, Antoine Girard, Mary Salvatore & Kathleen Capaccione. (2023) Advances in PET/CT Imaging for Breast Cancer. Journal of Clinical Medicine 12:13, pages 4537.
Crossref
Crossref
Fabian Krutzek, Cornelius K. Donat, Martin Ullrich, Kristof Zarschler, Marie-Charlotte Ludik, Anja Feldmann, Liliana R. Loureiro, Klaus Kopka & Sven Stadlbauer. (2023) Design and Biological Evaluation of Small-Molecule PET-Tracers for Imaging of Programmed Death Ligand 1. Cancers 15:9, pages 2638.
Crossref
Crossref
Elif Tugce SARCAN & Yekta ÖZER. (2023) Monoclonal Antibodies and Immuno-PET Imaging: An Overview. Fabad Journal of Pharmaceutical Sciences.
Crossref
Crossref
Chengrun Du, Jianyun Jiang, Caifeng Wan, Guangsen Pan, Fangfang Kong, Ruiping Zhai, Chaosu Hu & Hongmei Ying. (2022) AntiPD-L1 antibody conjugated Au-SPIOs nanoplatform for enhancing radiosensitivity and triggering anti-tumor immune response. Scientific Reports 12:1.
Crossref
Crossref
Danni Li, Xuran Li, Jun Zhao & Fei Tan. (2022) Advances in nuclear medicine-based molecular imaging in head and neck squamous cell carcinoma. Journal of Translational Medicine 20:1.
Crossref
Crossref
Qi Yao, Xinqi Ge, Zhichao Lu, Jinlong Shi, Jianhong Shen & Jian Chen. (2022) HAUS Augmin-Like Complex Subunit 1 Influences Tumour Microenvironment and Prognostic Outcomes in Glioma. Journal of Oncology 2022, pages 1-19.
Crossref
Crossref
Reyhaneh Manafi-Farid, Bahar Ataeinia, Shaghayegh Ranjbar, Zahra Jamshidi Araghi, Mohammad Mobin Moradi, Christian Pirich & Mohsen Beheshti. (2022) ImmunoPET: Antibody-Based PET Imaging in Solid Tumors. Frontiers in Medicine 9.
Crossref
Crossref
Fabian Krutzek, Klaus Kopka & Sven Stadlbauer. (2022) Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis. Pharmaceuticals 15:6, pages 747.
Crossref
Crossref
Fiona Hegi-Johnson, Stacey Rudd, Rodney J. Hicks, Dirk De Ruysscher, Joseph A. Trapani, Thomas John, Paul Donnelly, Benjamin Blyth, Gerard Hanna, Sarah Everitt, Peter Roselt & Michael P. MacManus. (2022) Imaging immunity in patients with cancer using positron emission tomography. npj Precision Oncology 6:1.
Crossref
Crossref
Zhongquan Cheng, Yang Du, Leyi Yu, Zhu Yuan & Jie Tian. (2022) Application of Noninvasive Imaging to Combined Immune Checkpoint Inhibitors for Breast Cancer: Facts and Future. Molecular Imaging and Biology 24:2, pages 264-279.
Crossref
Crossref
Federica Pisaneschi & Nerissa T. Viola. (2021) Development and Validation of a PET/SPECT Radiopharmaceutical in Oncology. Molecular Imaging and Biology 24:1, pages 1-7.
Crossref
Crossref
Zhonghua Liu, Michelle Williams, John Stewart, Bonnie S. Glisson, Clifton Fuller & Sinchita Roy‐Chowdhuri. (2021) Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma. Cancer Cytopathology 130:2, pages 110-119.
Crossref
Crossref
Anis Krache, Charlotte Fontan, Carine Pestourie, Manuel Bardiès, Yann Bouvet, Pierre Payoux, Etienne Chatelut, Melanie White-Koning & Anne-Sophie Salabert. (2022) Preclinical Pharmacokinetics and Dosimetry of an 89Zr Labelled Anti-PDL1 in an Orthotopic Lung Cancer Murine Model. Frontiers in Medicine 8.
Crossref
Crossref
Outi Keinänen, Aaron G. Nash, Samantha M. Sarrett, Mirkka Sarparanta, Jason S. Lewis & Brian M. Zeglis. 2020. Nuclear Oncology. Nuclear Oncology
1
48
.
Outi Keinänen, Aaron G. Nash, Samantha M. Sarrett, Mirkka Sarparanta, Jason S. Lewis & Brian M. Zeglis. 2022. Nuclear Oncology. Nuclear Oncology
169
216
.
Thiago Bueno de Oliveira, Alexcia Camila Braun, Ulisses Ribaldo Nicolau, Emne Ali Abdallah, Vanessa da Silva Alves, Victor Hugo Fonseca de Jesus, Vinicius Fernando Calsavara, Luiz Paulo Kowaslki & Ludmilla T. Domingos Chinen. (2021) Prognostic impact and potential predictive role of baseline circulating tumor cells in locally advanced head and neck squamous cell carcinoma. Oral Oncology 121, pages 105480.
Crossref
Crossref
Alizée Bouleau, Vincent Lebon & Charles Truillet. (2021) PET imaging of immune checkpoint proteins in oncology. Pharmacology & Therapeutics 222, pages 107786.
Crossref
Crossref
Songbing Qin, Yang Yu, Hui Guan, Yanling Yang, Fenghao Sun, Yan Sun, Jiaxing Zhu, Ligang Xing, Jinming Yu & Xiaorong Sun. (2021) A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with 68Ga-labeled PD-L1 targeted nanobody. Aging 13:9, pages 13006-13022.
Crossref
Crossref
Hadia Farrukh, Nader El-Sayes & Karen Mossman. (2021) Mechanisms of PD-L1 Regulation in Malignant and Virus-Infected Cells. International Journal of Molecular Sciences 22:9, pages 4893.
Crossref
Crossref
Virginia Liberini, Riccardo Laudicella, Martina Capozza, Martin W. Huellner, Irene A. Burger, Sergio Baldari, Enzo Terreno & Désirée Deandreis. (2021) The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers. Molecules 26:8, pages 2201.
Crossref
Crossref
Marisa Capitao, Justine Perrin, Sylvain Simon, Sébastien Gouard, Nicolas Chouin, Frank Bruchertseifer, Alfred Morgenstern, Latifa Rbah-Vidal, Michel Chérel, Emmanuel Scotet, Nathalie Labarrière, Yannick Guilloux & Joëlle Gaschet. (2021) Anti-Tumor Efficacy of PD-L1 Targeted Alpha-Particle Therapy in a Human Melanoma Xenograft Model. Cancers 13:6, pages 1256.
Crossref
Crossref
M. Simó-Perdigó, J.L. Vercher-Conejero, S. Viteri & M.J. García-Velloso. (2021) Inmunoterapia, cáncer y PET. Revista Española de Medicina Nuclear e Imagen Molecular 40:2, pages 123-135.
Crossref
Crossref
Kathryn M. Tully, Veronica L. Nagle, Joshua A. Korsen & Jason S. Lewis. 2021. Molecular Imaging. Molecular Imaging
547
562
.
Sridhar Nimmagadda. (2020) Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges. Cancers 12:11, pages 3173.
Crossref
Crossref
Caleb BridgwaterAnne GellerXiaoling HuJoe A. BurlisonHuang-Ge ZhangJun YanHaixun Guo. (2020)
89
Zr-Labeled Anti-PD-L1 Antibody Fragment for Evaluating
In Vivo
PD-L1 Levels in Melanoma Mouse Model
. Cancer Biotherapy and Radiopharmaceuticals 35:8, pages 549-557.
Crossref
Crossref
Susanne Lütje, Georg Feldmann, Markus Essler, Peter Brossart & Ralph A. Bundschuh. (2020) Immune Checkpoint Imaging in Oncology: A Game Changer Toward Personalized Immunotherapy?. Journal of Nuclear Medicine 61:8, pages 1137-1144.
Crossref
Crossref
Weijun Wei, Zachary T. Rosenkrans, Jianjun Liu, Gang Huang, Quan-Yong Luo & Weibo Cai. (2020) ImmunoPET: Concept, Design, and Applications. Chemical Reviews 120:8, pages 3787-3851.
Crossref
Crossref
Justine Perrin, Marisa Capitao, Marie Mougin-Degraef, François Guérard, Alain Faivre-Chauvet, Latifa Rbah-Vidal, Joëlle Gaschet, Yannick Guilloux, Françoise Kraeber-Bodéré, Michel Chérel & Jacques Barbet. (2020) Cell Tracking in Cancer Immunotherapy. Frontiers in Medicine 7.
Crossref
Crossref
Takumi Kumai, Hiroki Komatsuda, Yoshinori Minami & Yasuaki Harabuchi. (2020) Exceptional Response to PD-1 Blockade as First-Line Therapy in Head and Neck Squamous Cell Carcinoma. ORL 82:6, pages 343-350.
Crossref
Crossref
Sarah R. Verhoeff, Michel M. van den Heuvel, Carla M.L. van Herpen, Berber Piet, Erik H.J.G. Aarntzen & Sandra Heskamp. (2020) Programmed Cell Death-1/Ligand-1 PET Imaging. PET Clinics 15:1, pages 35-43.
Crossref
Crossref
Claudia Foray, Cristina Barca, Philipp Backhaus, Sonja Schelhaas, Alexandra Winkeler, Thomas Viel, Michael Schäfers, Oliver Grauer, Andreas H. Jacobs & Bastian Zinnhardt. 2020. Tumor Microenvironment. Tumor Microenvironment
71
87
.
Emily B. Ehlerding & Weibo Cai. 2020. Atlas of Response to Immunotherapy. Atlas of Response to Immunotherapy
119
127
.
Peter Wierstra, Gerwin Sandker, Erik Aarntzen, Martin Gotthardt, Gosse Adema, Johan Bussink, René Raavé & Sandra Heskamp. (2019) Tracers for non-invasive radionuclide imaging of immune checkpoint expression in cancer. EJNMMI Radiopharmacy and Chemistry 4:1.
Crossref
Crossref
Mathieu Sinigaglia, Tarek Assi, Florent L. Besson, Samy Ammari, Myriam Edjlali, Whitney Feltus, Laura Rozenblum-Beddok, Binsheng Zhao, Lawrence H. Schwartz, Fatima-Zohra Mokrane & Laurent Dercle. (2019) Imaging-guided precision medicine in glioblastoma patients treated with immune checkpoint modulators: research trend and future directions in the field of imaging biomarkers and artificial intelligence. EJNMMI Research 9:1.
Crossref
Crossref
Ryusuke Hori, Shogo Shinohara, Tsuyoshi Kojima, Hiroki Kagoshima, Morimasa Kitamura, Ichiro Tateya, Hisanobu Tamaki, Yohei Kumabe, Ryo Asato, Hiroyuki Harada, Yoshiharu Kitani, Takashi Tsujimura, Keigo Honda, Kazuyuki Ichimaru & Koichi Omori. (2019) Real-World Outcomes and Prognostic Factors in Patients Receiving Nivolumab Therapy for Recurrent or Metastatic Head and Neck Carcinoma. Cancers 11:9, pages 1317.
Crossref
Crossref
Angelo Castello & Egesta Lopci. (2019) Response assessment of bone metastatic disease: seeing the forest for the trees RECIST, PERCIST, iRECIST, and PCWG-2. The Quarterly Journal of Nuclear Medicine and Molecular Imaging 63:2.
Crossref
Crossref
Emily B. Ehlerding, Hye Jin Lee, Todd E. Barnhart, Dawei Jiang, Lei Kang, Douglas G. McNeel, Jonathan W. Engle & Weibo Cai. (2019)
Noninvasive Imaging and Quantification of Radiotherapy-Induced PD-L1 Upregulation with
89
Zr–Df–Atezolizumab
. Bioconjugate Chemistry 30:5, pages 1434-1441.
Crossref
Crossref
Alberto Signore, Chiara Lauri, Sveva Auletta, Kelly Anzola, Filippo Galli, Massimiliano Casali, Annibale Versari & Andor W.J.M. Glaudemans. (2019) Immuno-Imaging to Predict Treatment Response in Infection, Inflammation and Oncology. Journal of Clinical Medicine 8:5, pages 681.
Crossref
Crossref
Joo Hee Jang, Sang Jin Han, Jung Young Kim, Kwang Il Kim, Kyo Chul Lee & Chi Soo Kang. (2019)
Synthesis and Feasibility Evaluation of a new Trastuzumab Conjugate Integrated with Paclitaxel and
89
Zr for Theranostic Application Against HER2‐Expressing Breast Cancers
. ChemistryOpen 8:4, pages 451-456.
Crossref
Crossref
Elaine M. Jagoda, Olga Vasalatiy, Falguni Basuli, Ana Christina L. Opina, Mark R. Williams, Karen Wong, Kelly C. Lane, Steve Adler, Anita Thein Ton, Lawrence P. Szajek, Biying Xu, Donna Butcher, Elijah F. Edmondson, Rolf E. Swenson, John Greiner, James Gulley, Janet Eary & Peter L. Choyke. (2019) Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab. Molecular Imaging 18, pages 153601211982998.
Crossref
Crossref
Sandra Heskamp, Peter J. Wierstra, Janneke D.M. Molkenboer-Kuenen, Gerwin W. Sandker, Soley Thordardottir, Jeannette Cany, Daniel Olive, Johan Bussink, Otto C. Boerman, Harry Dolstra, Erik H.J.G. Aarntzen & Willemijn A. Hobo. (2019) PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer. Cancer Immunology Research 7:1, pages 150-161.
Crossref
Crossref
Kevin Allen, Rubin Jiao, Mackenzie Malo, Connor Frank & Ekaterina Dadachova. (2018) Biodistribution of a Radiolabeled Antibody in Mice as an Approach to Evaluating Antibody Pharmacokinetics. Pharmaceutics 10:4, pages 262.
Crossref
Crossref
Jaeyeon Choi, Wissam Beaino, Ronald J. Fecek, Kellsye P.L. Fabian, Charles M. Laymon, Brenda F. Kurland, Walter J. Storkus & Carolyn J. Anderson. (2018) Combined VLA-4–Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma. Journal of Nuclear Medicine 59:12, pages 1843-1849.
Crossref
Crossref
Weimin Lin, Miao Chen, Le Hong, Hang Zhao & Qianming Chen. (2018) Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC. Frontiers in Oncology 8.
Crossref
Crossref
Elly L. van der Veen, Frederike Bensch, Andor W.J.M. Glaudemans, Marjolijn N. Lub-de Hooge & Elisabeth G.E. de Vries. (2018) Molecular imaging to enlighten cancer immunotherapies and underlying involved processes. Cancer Treatment Reviews 70, pages 232-244.
Crossref
Crossref
Heather M. Gibson, Brooke N. McKnight, Agnes Malysa, Greg Dyson, Wendy N. Wiesend, Claire E. McCarthy, Joyce Reyes, Wei-Zen Wei & Nerissa T. Viola-Villegas. (2018) IFNγ PET Imaging as a Predictive Tool for Monitoring Response to Tumor Immunotherapy. Cancer Research 78:19, pages 5706-5717.
Crossref
Crossref
Mengxin Xu, Yuxiang Han, Guizhong Liu, Yang Xu, Dongban Duan, Hui Liu, Felix Du, Peter Luo & Zhibo Liu. (2018) Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy. Molecular Pharmaceutics 15:10, pages 4426-4433.
Crossref
Crossref
Benjamin Solomon, Richard J. Young & Danny Rischin. (2018) Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. Seminars in Cancer Biology 52, pages 228-240.
Crossref
Crossref
Ariel E. Marciscano & Daniel L.J. Thorek. (2018) Role of noninvasive molecular imaging in determining response. Advances in Radiation Oncology 3:4, pages 534-547.
Crossref
Crossref
Lorenzo Galluzzi, Timothy A. Chan, Guido Kroemer, Jedd D. Wolchok & Alejandro López-Soto. (2018) The hallmarks of successful anticancer immunotherapy. Science Translational Medicine 10:459.
Crossref
Crossref
Aaron T. Mayer & Sanjiv S. Gambhir. (2018) The Immunoimaging Toolbox. Journal of Nuclear Medicine 59:8, pages 1174-1182.
Crossref
Crossref
Kristina Buder-Bakhaya & Jessica C. Hassel. (2018) Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond. Frontiers in Immunology 9.
Crossref
Crossref
Julio A. Diaz-Perez, Mara G. Beveridge, Thomas A. Victor & Thomas L. Cibull. (2018) Granulomatous and lichenoid dermatitis after IgG4 anti-PD-1 monoclonal antibody therapy for advanced cancer. Journal of Cutaneous Pathology 45:6, pages 434-438.
Crossref
Crossref
Aaron T. Mayer & Sanjiv S. Gambhir. (2018) Reply: Optimizing Strategies for Immune Checkpoint Imaging with Immuno-PET in Preclinical Study. Journal of Nuclear Medicine 59:4, pages 711.2-712.
Crossref
Crossref
Arlene Siefker-Radtke & Brendan Curti. (2017) Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition. Nature Reviews Urology 15:2, pages 112-124.
Crossref
Crossref
Masahiro Kikuchi. (2018) Clinical Usefulness of Positron Emission Tomography for Head and Neck Cancer from Current to Near Future頭頸部癌診療におけるPET検査の現状と近未来. Practica Oto-Rhino-Laryngologica 111:12, pages 789-802.
Crossref
Crossref